Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106639 · ClinicalTrials.gov registry record · Phase 2
A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00106639 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 61 participants.
The verdict
NCT00106639, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
This Phase 2 study was designed to evaluate the safety and efficacy of 2 dose levels of CP-690,550 (15 mg twice daily and 30 mg twice) against tacrolimus, in combination with basiliximab induction, mycophenolate mofetil and corticosteroids, in kidney transplant patients. Stage 1 was to randomize approximately 54 subjects. After all Stage 1 subjects had completed 6 months of treatment, Stage 2 was to randomize an additional 195 subjects to the same treatment groups.
Interventions
- DRUG tacrolimus
- DRUG CP-690,550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106639
The ClinicalTrials.gov registry entry for NCT00106639 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tacrolimus is the first listed.
NCT00106639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106639 about?
NCT00106639 is a clinical study titled "A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients". This Phase 2 study was designed to evaluate the safety and efficacy of 2 dose levels of CP-690,550 (15 mg twice daily and 30 mg twice) against tacrolimus, in combination with basiliximab induction, mycophenolate mofetil and corticosteroids, in kidney transplant patients. Stage 1 was to randomize app...
What is the current status of trial NCT00106639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2005-05. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00106639?
The interventions under investigation include: tacrolimus (DRUG), CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT00106639?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.